ATLANTA, May 1, 2024 /PRNewswire/ -- Optomed USA, Inc., a medical technology company, introduces the Optomed Aurora AEYE, a handheld AI fundus camera that provides instant detection of more than mild diabetic retinopathy. With the Optomed Aurora AEYE, diabetic patients in the primary care setting can now get on-the spot eye screenings and immediate retinopathy detection before being referred to an eye care professional..

亚特兰大，2024年5月1日/PRNewswire/-Optomed USA，Inc.，一家医疗技术公司，推出了Optomed Aurora AEYE，一种手持式AI眼底照相机，可即时检测多种轻度糖尿病视网膜病变。使用Optomed Aurora AEYE，初级保健环境中的糖尿病患者现在可以在被转介给眼科专业人员之前进行现场眼部筛查和立即视网膜病变检测。。

Continue Reading

继续阅读

The first FDA-cleared handheld AI fundus camera for the detection of more than mild diabetic retinopathy.

FDA批准的第一台手持式AI眼底照相机用于检测轻度以上的糖尿病视网膜病变。

Optomed Aurora with AEYE-DS is the only FDA-cleared handheld AI fundus camera. Recent clinical trials demonstrated that the Optomed Aurora AEYE handheld camera exhibits diagnostic sensitivity was in the range of 92%-93% and specificity was in the range of 89%-94%. In both studies, over 99% of patients received a diagnostic result.

带有AEYE-DS的Optomed Aurora是唯一获得FDA批准的手持式AI眼底照相机。最近的临床试验表明，Optomed Aurora AEYE手持式相机的诊断灵敏度在92%〜93%之间，特异性在89%〜94%之间。在这两项研究中，超过99%的患者获得了诊断结果。

Its non-mydriatic and single image per eye operation offers quick and accurate screening. Its high-contrast optical design is engineered to detect small early-phase retinal changes with a 50-degree field-of-view. The ease-of-use is further increased by autofocus and auto exposure functions. It has the capability to capture digital images that can easily be sent to eye care providers..

它的非散瞳和每只眼睛操作的单一图像提供了快速准确的筛查。它的高对比度光学设计旨在以50度的视野检测早期视网膜的微小变化。自动对焦和自动曝光功能进一步提高了易用性。它具有捕获数字图像的能力，可以轻松地发送给眼部护理提供商。。

Nearly 50% of the 38.4 million Americans who have diabetes skip their annual eye exams, leaving them vulnerable to diabetic retinopathy and blindness. Autonomous screening in primary care can improve clinic adherence to HEDIS measurements, is reimbursable, and ultimately can prevent blindness in diabetics at risk for vision loss..

在3840万患有糖尿病的美国人中，近50%的人跳过了年度眼科检查，使他们容易患糖尿病性视网膜病变和失明。初级保健中的自主筛查可以提高临床对HEDIS测量的依从性，是可以报销的，并最终可以预防有视力丧失风险的糖尿病患者失明。。

'The Optomed Aurora AEYE gives primary care providers the opportunity to bridge the diabetic retinopathy gap in the US with immediate, on-the-spot detection of diabetic retinopathy with results in about 60 seconds,' said David Frasch, Managing Director. 'This technology removes the guesswork out of when it is necessary to refer a patient to an eye care provider. Results with the Optomed Aurora AEYE are simple: red means you refer to an eye care specialist, and green means you screen again in 12 months.'About Optomed Optomed USA, Inc.

“Optomed Aurora AEYE为初级保健提供者提供了弥合美国糖尿病视网膜病变差距的机会，即时、现场检测糖尿病视网膜病变，结果约60秒，”总经理大卫·弗拉希（DavidFrasch）说这项技术消除了在需要将患者转介给眼科护理提供者时的猜测。使用Optomed Aurora AEYE的结果很简单：红色表示您需要咨询眼科护理专家，绿色表示您在12个月内再次进行筛查。”关于Optomed Optomed USA，Inc。

a wholly owned subsidiary of Optomed Plc, a Finnish medical technology company and one of the leading providers of handheld fundus cameras worldwide. Optomed Plc combines handheld screening devices with software and optional artificial intelligence integration with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy.

Optomed Plc是芬兰医疗技术公司Optomed Plc的全资子公司，也是全球手持式眼底照相机的领先供应商之一。Optomed Plc将手持筛查设备与软件和可选的人工智能集成相结合，旨在改变快速增加的糖尿病视网膜病变等致盲性眼病的诊断过程。

In its business, Optomed Plc focuses on eye-screening devices and software solutions-related R&D in Finland, and sales through different channels in over 60 countries. Forward-Looking Statements This press release includes forward-looking statements concerning future events. These statements involve risks and uncertainties, and actual results may differ from those expressed or implied.

在其业务中，Optomed Plc在芬兰专注于眼筛查设备和软件解决方案相关的研发，并通过不同渠道在60多个国家销售。前瞻性声明本新闻稿包括有关未来事件的前瞻性声明。这些陈述涉及风险和不确定性，实际结果可能与明示或暗示的结果不同。

Factors beyond the control of Optomed Plc and its affiliates may affect future performance. Optomed Plc and its affiliates rely on third parties for certain activities, and delays may occur if these parties fail to meet obligations, regulatory requirements, or deadlines. Optomed Plc and its affiliates do not commit to updating forward-looking statements considering future events or changes in expectations.Contact Information Optomed USA, Inc.Theresa Matson626-437-5950theresa.matson@.

Optomed Plc及其附属公司无法控制的因素可能会影响未来的表现。Optomed Plc及其附属公司在某些活动中依赖第三方，如果这些第三方未能履行义务、监管要求或截止日期，则可能会出现延误。Optomed Plc及其附属公司不承诺在考虑未来事件或预期变化的情况下更新前瞻性声明。联系信息Optomed USA，Inc.TheresaMatson626-437-5950theresa.matson@.